- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.06. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| CYTOMED THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.06. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.05. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.04. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.03. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.03. | CytoMed Therapeutics Ltd - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 28.01. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.01. | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress | 467 | GlobeNewswire (Europe) | SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 13.01. | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics' new year update and seeks shareholders' feedback on proposal to improve shareholder value for their patient capital | 396 | GlobeNewswire (Europe) | SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 08.12.25 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology ... | 182 | GlobeNewswire (Europe) | SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 18.11.25 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India | 757 | GlobeNewswire (Europe) | SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 28.08.25 | CYTOMED THERAPEUTICS LIMITED: Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition | 511 | GlobeNewswire (Europe) | SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 21.07.25 | CYTOMED THERAPEUTICS LIMITED: Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or ... | 312 | GlobeNewswire (Europe) | SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 6,330 | +0,19 % | CLINUVEL PHARMACEUTICALS LIMITED: SCENESSE approved for EPP in Canada | ||
| EDITAS MEDICINE | 2,640 | -4,69 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,906 | -1,20 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| CELLECTAR BIOSCIENCES | 2,650 | +0,76 % | Cellectar Biosciences, Inc. - 8-K, Current Report | ||
| CYTODYN | 0,192 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,170 | -1,76 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 6,960 | -1,14 % | Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy | GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the... ► Artikel lesen | |
| DENALI THERAPEUTICS | 22,320 | -4,08 % | JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating | ||
| CEL-SCI | 1,100 | -1,79 % | CEL-SCI launches confirmatory study for head and neck cancer drug | ||
| CYTOKINETICS | 71,20 | -1,41 % | Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure? | ||
| COHERUS ONCOLOGY | 1,399 | +7,95 % | Coherus Oncology, Inc.: Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical... ► Artikel lesen | |
| CURIS | 4,510 | +9,17 % | XFRA CUS1: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,206 | -1,23 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,754 | +3,92 % | Fate Therapeutics, Inc.: Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate | First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited... ► Artikel lesen | |
| FAETH THERAPEUTICS | 33,430 | +0,21 % | Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer | - Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement -
- Company changed name to Faeth... ► Artikel lesen |
Das Unternehmen CYTOMED THERAPEUTICS LIMITED kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -7,51 % bei einem Aktienkurs von 0,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTOMED THERAPEUTICS LIMITED finden Sie auf Wallstreet Online.